Home Cart Sign in  
Chemical Structure| 1184-78-7 Chemical Structure| 1184-78-7

Structure of Trimethylamine N-oxide
CAS No.: 1184-78-7

Chemical Structure| 1184-78-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Trimethylamine N-oxide can activate ROS/NLRP3 inflammasome-induced inflammation and promote fibroblast differentiation and cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.

Synonyms: NSC 408426; TMAO

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Trimethylamine N-oxide

CAS No. :1184-78-7
Formula : C3H9NO
M.W : 75.11
SMILES Code : C[N+](C)([O-])C
Synonyms :
NSC 408426; TMAO
MDL No. :MFCD00002048
InChI Key :UYPYRKYUKCHHIB-UHFFFAOYSA-N
Pubchem ID :1145

Safety of Trimethylamine N-oxide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P280-P304+P340+P312-P337+P313-P403+P233

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MC3T3-E1 osteoblasts 50 µM, 100 µM, 200 µM, 300 µM 1 day or 18 days To investigate the effect of TMAO on osteoblast proliferation and differentiation, results showed that TMAO dose-dependently inhibited osteoblast proliferation and mineralized matrix production. Cell Mol Life Sci. 2024 Dec 24;82(1):13
Human umbilical vein endothelial cells (HUVEC) 400 µM 12 hours To investigate the effect of TMAO on oxidative stress and inflammatory injury in HUVECs. Results showed that TMAO promoted oxidative stress and inflammatory injury by activating the MAPK/Nrf2-Keap1 signaling pathway, inhibiting HUVEC migration and angiogenesis. Gut Microbes. 2024 Jan-Dec;16(1):2311888
HCMEC/D3 cells 0.4 µM - 40 µM 24 hours To evaluate the effects of TMA and TMAO on BBB integrity. TMA increased paracellular permeability, while TMAO at physiological concentrations reduced permeability and enhanced TEER. Microbiome. 2021 Nov 27;9(1):235
Mouse vascular smooth muscle cells (VSMC) 100 µM 24 hours TMAO enhances Ang II-induced intracellular Ca2+ release via activation of the PERK/ROS/CaMKII/PLCβ3 pathway. Redox Biol. 2021 Oct;46:102115.
Human placental trophoblast cells (HTR-8/SVneo) 200 µM 48 hours To investigate the effect of TMAO on oxidative stress and inflammatory injury in HTR-8/SVneo cells. Results showed that TMAO promoted oxidative stress and inflammatory injury by activating the MAPK/Nrf2-Keap1 signaling pathway, inhibiting HTR-8/SVneo cell migration and invasion. Gut Microbes. 2024 Jan-Dec;16(1):2311888
Mouse carotid artery 25 µM, 50 µM, 100 µM 60 minutes To evaluate the effect of TMAO on endothelium-dependent dilation in mouse carotid arteries. Results showed that TMAO concentration-dependently impaired endothelium-dependent dilation, and this impairment was reversed by the superoxide dismutase mimetic TEMPOL. Hypertension. 2020 Jul;76(1):101-112

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Photochemical ischemic stroke model and Middle Cerebral Artery Occlusion (MCAO) model Oral 0.12% (w/w) TMAO or 1.00% (w/w) choline 3 weeks TMAO and choline supplementation significantly increased cerebral infarct size and exacerbated post-stroke functional deficits. Cell Host Microbe. 2021 Jul 14;29(7):1199-1208. e5
Mice Male C57BL/6N mice Dietary supplementation 0.12% TMAO 6 months To evaluate the effect of long-term dietary TMAO supplementation on vascular endothelial function in young mice. Results showed that TMAO supplementation impaired endothelium-dependent dilation, accompanied by increased vascular oxidative stress, and this impairment was reversed by the superoxide dismutase mimetic TEMPOL. Hypertension. 2020 Jul;76(1):101-112
C57BL/6 mice High-fat diet-induced obesity model Oral 0.2% TMAO Consecutive 3 months To investigate the effect of TMAO on bone mass loss, results showed that TMAO accelerated bone mass loss, inhibited bone formation and promoted bone resorption. Cell Mol Life Sci. 2024 Dec 24;82(1):13
Female Sprague-Dawley rats High-fat diet-induced sarcopenic obesity model in natural aging rats Oral administration via drinking water 1% (V/V) TMAO Daily administration for 16 weeks TMAO aggravates high-fat diet-induced sarcopenic obesity via the ROS-AKT/mTOR signaling pathway J Adv Res. 2025 Apr;70:405-422
C57Bl/6 mice Ang II-induced hypertension model Drinking water 1% TMAO For 14 days TMAO aggravates Ang II-induced hypertension and enhances vasoconstriction via the PERK/ROS/CaMKII/PLCβ3 axis. Redox Biol. 2021 Oct;46:102115.
C57Bl/6J mice Inflammatory model Intraperitoneal injection 1.8 mg/kg Single injection or long-term administration in drinking water To evaluate the effects of TMAO on BBB integrity and cognitive function. TMAO enhanced BBB integrity in acute inflammatory models and protected cognitive function during chronic inflammatory challenges. Microbiome. 2021 Nov 27;9(1):235
C57BL/6J mice Non-alcoholic steatohepatitis (NASH) model Intraperitoneal injection 75 mg/kg/day Once daily for three months To evaluate the effect of TMAO on liver fibrosis in NASH model mice. Results showed that TMAO significantly alleviated liver fibrosis, improved liver function, and restored gut microbiota diversity. Front Immunol. 2022 Aug 22;13:964477

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

13.31mL

2.66mL

1.33mL

66.57mL

13.31mL

6.66mL

133.14mL

26.63mL

13.31mL

References

 

Historical Records